Status:
COMPLETED
Oral Nicorandil for Prevention of No Reflow Phenomenon in Anterior STEMI Patients Undergoing PPCI
Lead Sponsor:
Ain Shams University
Collaborating Sponsors:
Misr University for Science and Technology
Conditions:
No Reflow Phenomenon
Anterior STEMI
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Aim of the study is to Investigate the potential role of oral nicorandil in preventing the No reflow phenomenon in anterior ST-segment elevation myocardial infarction (STEMI) patients undergoing percu...
Detailed Description
This is a randomized, controlled clinical trial designed to evaluate the efficacy of a single oral dose of nicorandil in preventing the no-reflow phenomenon in patients with anterior ST-segment elevat...
Eligibility Criteria
Inclusion
- Age \> 18 years
- Patients diagnosed with anterior ST-segment elevation myocardial infarction (STEMI).
- Individuals scheduled for percutaneous coronary intervention (PPCI).
- Presence of risk factors or indications for preventing the No reflow phenomenon.
- Willingness and ability to comply with the study protocol.
- Ability to provide informed consent for participation in the study.
Exclusion
- Known allergic reaction to oral nicorandil.
- Concomitant use of medications that may interact with nicorandil.
- Presence of contraindications to oral nicorandil such as hypotension, hepatic or renal impairment
- Need for emergent coronary artery bypass grafting.
Key Trial Info
Start Date :
March 10 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2025
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT07138508
Start Date
March 10 2024
End Date
March 1 2025
Last Update
August 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain shams University hospitals
Cairo, Egypt